08:43 AM EST - Eupraxia Pharmaceuticals Inc. : Announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading unchanged at $10.13.
